Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis

Abstract Objectives: Infliximab is effective in patients with ulcerative colitis (UC); however, one-third of patients do not respond and require additional therapies such as other biologic agents. Therefore, the aim of this study was to analyze the association between pro-inflammatory molecules and clinical efficacy to elucidate possible mechanisms for the non-response to infliximab to aid in treatment selection. Materials and method: Patients with moderate-to-severe active UC receiving infliximab in our hospital between 2010 and 2016 for whom pre-treatment serum samples were available were retrospectively evaluated. We analyzed the association between serum interleukin (IL)-6, tumor necrosis factor-α (TNF-α) and soluble mucosal vascular addressin cell adhesion molecule-1 (sMAdCAM-1) and the clinical efficacy of infliximab. The primary endpoint was clinical response at the end of the induction period. Results: Forty-one patients were included in this study. After induction therapy, 27 patients (65.9%) showed a clinical response. Serum IL-6 levels were significantly lower in responders than in non-responders (p = .012), whereas no significant differences were noted in other factors including sMAdCAM-1 and TNF-α. Multivariate analysis identified that serum IL-6 level (odds ratio = 0.72; 95% confidence interval, 0.54–0.96; p = .027) was independently associated with response to infliximab. Conclusions: Serum IL-6 level is associated with response to infliximab in UC. Elevated concentrations of IL-6 may provide insight to the mechanism of non-response to infliximab.

[1]  T. Molnár,et al.  Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. , 2017, Journal of Crohn's & colitis.

[2]  K. Tominaga,et al.  Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis , 2017, PloS one.

[3]  A. Morita,et al.  Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis , 2016, Modern rheumatology.

[4]  W. Sandborn,et al.  Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. , 2017, The New England journal of medicine.

[5]  T. Molnár,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. , 2017, Journal of Crohn's & colitis.

[6]  H. Bliddal,et al.  Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study , 2016, PloS one.

[7]  W. Cai,et al.  Neutralization of IL-6 and TNF-α ameliorates intestinal permeability in DSS-induced colitis. , 2016, Cytokine.

[8]  U. Kopylov,et al.  Advances in the development of new biologics in inflammatory bowel disease , 2016, Annals of gastroenterology.

[9]  T. Chiba,et al.  Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis , 2015, Journal of gastroenterology and hepatology.

[10]  T. Matsui,et al.  Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial , 2015, Inflammatory bowel diseases.

[11]  C. Ponsioen,et al.  Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. , 2015, Gastroenterology.

[12]  H. Ogata,et al.  First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis , 2015, Journal of Gastroenterology.

[13]  L. Öhman,et al.  Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy , 2015, Scandinavian journal of gastroenterology.

[14]  L. Peyrin-Biroulet,et al.  Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study , 2014, Gut.

[15]  Ji Won Kim,et al.  Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study , 2013, Journal of gastroenterology and hepatology.

[16]  A. Griffiths,et al.  Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. , 2013, Journal of Crohn's & colitis.

[17]  G. Fiorino,et al.  Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside. , 2013, Current drug targets.

[18]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[19]  G. Corazza,et al.  Effect of Tumor Necrosis Factor-&agr; Blockade on Mucosal Addressin Cell-adhesion Molecule-1 in Crohn's Disease , 2013, Inflammatory bowel diseases.

[20]  G. D'Haens,et al.  One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2 , 2013, Alimentary pharmacology & therapeutics.

[21]  J. Gisbert,et al.  Systematic review: antibodies and anti‐TNF‐α levels in inflammatory bowel disease , 2012, Alimentary pharmacology & therapeutics.

[22]  D. Mould,et al.  Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms , 2012, Clinical pharmacology and therapeutics.

[23]  J. Gisbert,et al.  Infliximab salvage therapy after failure of ciclosporin in corticosteroid‐refractory ulcerative colitis: a multicentre study , 2012, Alimentary pharmacology & therapeutics.

[24]  C. Weston,et al.  Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity , 2011, Hepatology.

[25]  B. Flourié,et al.  A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization , 2010, The American Journal of Gastroenterology.

[26]  F. Pallone,et al.  Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases. , 2010, Current pharmaceutical design.

[27]  S. Brand,et al.  Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis , 2010, The American Journal of Gastroenterology.

[28]  A. Olson,et al.  Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. , 2010, International journal of clinical pharmacology and therapeutics.

[29]  G Van Assche,et al.  Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis , 2009, Gut.

[30]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[31]  J. Ellenberg,et al.  Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.

[32]  F. Ingegnoli,et al.  Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. , 2008, Journal of autoimmunity.

[33]  K. Van Steen,et al.  Long-term outcome after infliximab for refractory ulcerative colitis. , 2008, Journal of Crohn's & colitis.

[34]  M. Ribolsi,et al.  Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. , 2007, World journal of gastroenterology.

[35]  M. Neurath,et al.  Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. , 2007, Inflammatory bowel diseases.

[36]  Konstantinos H. Katsanos,et al.  Predictors of early response to infliximab in patients with ulcerative colitis , 2007, Inflammatory bowel diseases.

[37]  R. Sartor.  Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[38]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[39]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[40]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[41]  S. Hanauer.  Medical therapy for ulcerative colitis 2004. , 2004, Gastroenterology.

[42]  J. Lewis,et al.  Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis , 2002, American Journal of Gastroenterology.

[43]  A. Torii,et al.  Differential expression of mucosal addressin cell adhesion molecule‐1 (MAdCAM‐1) in ulcerative colitis and Crohn's disease , 2002, Pathology international.

[44]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[45]  C. Elia,et al.  Expression of lymphocyte-endothelial receptor-ligand pairs, α4β7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease , 1999, Gut.

[46]  T. Sawada,et al.  [Medical therapy in ulcerative colitis]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.

[47]  F. Breedveld,et al.  Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. , 1999, Journal of immunology.

[48]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[49]  H. Hodgson,et al.  Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. , 1994, Gut.

[50]  C. Uyttenhove,et al.  T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor , 1988, The Journal of experimental medicine.

[51]  A Muraguchi,et al.  The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells , 1988, The Journal of experimental medicine.

[52]  S. Clark,et al.  B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. , 1988, Journal of immunology.

[53]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.

[54]  C. FordAlexander,et al.  ULCERATIVE colitis. , 1997, Journal of the American Medical Association.